Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
20.5.2021 00:14:00 EEST | Business Wire | Press release
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021.
“We look forward to presenting data from across Incyte’s oncology portfolio and partner programs at this year’s ASCO Annual Meeting,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data being presented during this congress, including new three-year data from the L-MIND study of tafasitamab in relapsed or refractory diffuse large B-cell lymphoma as well as results of the OPTIC study of ponatinib in chronic phase-chronic myeloid leukemia, underscore our continued focus on advancing science to help meet patients’ needs.”
Key abstracts accepted by ASCO include:
Oral Presentations
Ponatinib
OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)1 (Abstract #7000. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Poster Discussions
Tafasitamab
Long-Term Analyses from L-MIND, a Phase 2 Study of Tafasitamab (MOR208) Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)2 (Abstract #7513. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
Capmatinib
Capmatinib in MET Exon 14-Mutated, Advanced NSCLC: Updated Results from the GEOMETRY Mono-1 Study3 (Abstract #9020. Session: Lung Cancer—Non-Small Cell Metastatic.)
ePosters
Capmatinib
Capmatinib Efficacy in Patients with NSCLC Identified as METex14 Using an NGS-Based Liquid Biopsy Assay: Results from the GEOMETRY Mono-1 Study3 (Abstract #9111. Session: Lung Cancer—Non-Small Cell Metastatic.)
Patient-Reported Outcomes in Capmatinib-Treated Patients with METex14-Mutated Advanced NSCLC: Results from the Phase 2 GEOMETRY Mono-1 Study3 (Abstract #9056. Session: Lung Cancer—Non-Small Cell Metastatic.)
Phase 1b/2 Study of Capmatinib Plus Gefitinib in Patients with EGFR-Mutated, MET-Dysregulated Non–Small Cell Lung Cancer who Received Prior Therapy: Final Overall Survival and Safety3 (Abstract #9048. Session: Lung Cancer—Non-Small Cell Metastatic.)
Pemigatinib
Pemigatinib for Previously Treated Locally Advanced/Metastatic Cholangiocarcinoma (CCA): Update of FIGHT-202 (Abstract #4086. Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary.)
Retifanlimab
Phase 2 Study of Retifanlimab (INCMGA00012) in Patients (Pts) with Selected Solid Tumors (POD1UM-203) (Abstract #2571. Session: Developmental Therapeutics—Immunotherapy.)
Ruxolitinib-Parsaclisib Combination Studies
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naïve Myelofibrosis (Abstract #TPS7058. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Tafasitamab
A Phase 3 Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) (Abstract #TPS7568. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
First-MIND: A Phase 1b, Open-Label, Randomized Study to Assess Safety of Tafasitamab (tafa) or Tafa + Lenalidomide (LEN) in Addition to R‑CHOP in Patients with Newly Diagnosed DLBCL2 (Abstract #7540. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
For full session details and data presentation listings, please see the ASCO21 online program at https://meetinglibrary.asco.org. Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, June 4, 2021 at 9:00 a.m. ET.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the FDA and other regulatory authorities outside of the United States; the Company’s dependence on its relationships with its collaboration partners; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020 and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Takeda-sponsored abstract.
2 MorphoSys-sponsored abstract.
3 Novartis-sponsored abstract.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005952/en/
Contact information
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perpetuals Reports $ 4.5 Billion in UpsideOnly Volume and Signs Exchange Agreement With Datavault AI for Tokenized Commodities2.6.2026 15:00:00 EEST | Press release
Perpetuals.com Ltd (Nasdaq: PDC) today reported strong early results for its breakout UpsideOnly trading and market prediction platform and announced an agreement with Datavault AI Inc. (Nasdaq: DVLT) to list tokenized real-world commodity assets on the Perpetuals platform. In its first two weeks, traders flocked to the UpsideOnly platform, attracting more than 30,000 active users, generating $4.5 billion in cumulative platform volume across 186,000 fills and 25 instruments. Reflecting the widespread demand for a risk-free product, users came from 185 different countries. Surprisingly, gold was the top instrument with $1.4 billion in volume, outpacing bitcoin at $1.2 billion with precious metals accounting for roughly 35 percent of total platform activity. UpsideOnly is the first trading and market prediction platform where users can't lose. Traders make predictions across global markets and share in profits when those predictions are validated by Perpetuals's proprietary AI, without e
Phenom Positioned as Strategic Leader in Fosway 9-Grid™ for Talent Acquisition Sixth Consecutive Year2.6.2026 15:00:00 EEST | Press release
Phenom, the leader in applied AI with an infrastructure built specifically to redesign work operations, has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602897994/en/ Phenom has been positioned as a Strategic Leader in the 2026 Fosway 9-Grid™ for Talent Acquisition for the sixth year in a row. The positioning reinforces Phenom’s focus on sustained execution and customer impact at a moment when most enterprises remain stuck between AI ambition and AI that works. The execution gap is well documented. Fosway’s recent AI Market Assessment for Talent Acquisition found that only 27% of AI features claimed by talent acquisition vendors are actu
How Fit Analytics Innovation Reclaimed its Independence to Build the Future of AI Commerce2.6.2026 14:47:00 EEST | Press release
With today’s launch of the AI Shopping Assistant, Fit Analytics Innovation moves beyond the AI-hype-cycle to deliver the conversational guidance modern apparel shoppers crave. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602315868/en/ AI Shopping Assistant - Fit Analytics Innovation Two years ago, Fit Analytics Innovation did the unthinkable: they bought themselves back. Following a high-profile acquisition by Snap Inc., the management team recovered the award-winning Fit Finder and secured sixteen years of expertise and data insights. That bet on independence has culminated in the launch of the AI Shopping Assistant, the latest module available as part of their expanded product suite. Delivering Performance Over P.R. Unlike "overnight" AI startups rushing for market share, Fit Analytics has utilized its independence to prioritize depth over hype. The resulting AI Shopping Assistant is a native evolution of the company’
Kinaxis Introduces Forward Deployed Engineering to Help Enterprises Turn Decisions into Outcomes2.6.2026 14:01:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain planning and orchestration, today introduced Forward Deployed Engineering (FDE), a new engagement model designed to help enterprises operationalize AI and translate decisions into measurable business outcomes. FDE reflects the broader Kinaxis vision for operational orchestration, an approach that coordinates signals, decisions, actions and learnings across the business fast enough to change outcomes. The opening keynote at Kinexions, the company’s global customer conference, delivered by CEO Razat Gaurav will be livestreamed globally on June 2 @ 11:30 am EST via LinkedIn Live. This approach combines a unified data foundation with semantic intelligence that understands the relationships, dependencies, and trade-offs that shape enterprise operations. Together, these capabilities help organizations move beyond isolated decision-making to coordinated execution, connecting data, systems, teams, and actions across the enterprise. Tradi
NIQ Launches Product Intelligence to Power AI-Driven Commerce2.6.2026 14:00:00 EEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Product Intelligence, a new solution designed to help retailers and brands transform fragmented product data into structured, interoperable intelligence that fuels AI-driven commerce. As AI increasingly shapes how consumers discover, evaluate, and purchase products, the quality and completeness of product data have become a defining competitive advantage. In AI-mediated commerce environments, products that lack structured, enriched, and machine-readable data risk becoming invisible to recommendation engines, AI assistants, and autonomous purchasing agents. NIQ Product Intelligence addresses this challenge by creating a unified product intelligence layer that standardizes attributes, resolves product identity across systems, and enriches product data at scale, enabling AI systems to better understand, match, recommend, and surface products across digital and physical commerce channels. For example, a traditional keyword search may
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom